Taltz® (Ixekizumab)

Para consultar la información para prescribir completa de Taltz® (Ixekizumab) de clic en el siguiente enlace: Información para prescribir

La información es proporcionada en respuesta a su solicitud, y puede contener datos relacionados a dosis, usos, formulaciones y poblaciones diferentes a la Información para Prescribir del producto. Consulte la Información para Prescribir en la liga que aparece arriba.

Ixekizumab: Biomarker Availability

Lilly has not tested biomarkers in Phase 3 clinical trials. There are no commercial labs available.

MX_cFAQ_IXE388_BIOMARKER_AVAILABILITY
MX_cFAQ_IXE388_BIOMARKER_AVAILABILITY
es-MX

The information contained in this letter may not completely match the current local labeling for IXEKIZUMAB. Please see local labeling approved in your country.

Phase 2 clinical trials

A biomarker to predict future response to ixekizumab therapy was investigated in a single phase 2 study and has not been replicated. This experiment evaluated the correlation between baseline mRNA expression of TRGV and clinical response to ixekizumab in patients with chronic moderate-to-severe plaque psoriasis. 1

There are no current commercial labs that test for TRGV levels, and there are no standards that would define high levels of TRGV.1

Phase 3 clinical trials

Lilly has not tested biomarkers in phase 3 studies. 

Reference

1Krueger JG., Suarez-Farinas M, Beselin A, et al. Baseline expression of T cell receptor gamma-V gene family is associated with high levels of response to ixekizumab treatment in psoriasis. J Invest Dermatol 2015; 135: S32-S32. http://www.jidonline.org/article/S0022-202X(15)60202-0/pdf

Glossary

Lilly = Eli Lilly and Company

TRGV =  T cell receptor gamma-V

Fecha de la última revisión: 2019 M03 04


Contáctenos para saber más de la información Médica de Lilly

Contacto vía correo electrónico

Correo electrónico: infomed@lilly.com

Envíe su consulta

Escriba su consulta